Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-country, Randomized, Double-blind, Placebo-controlled Trial to Evaluate Safety and Immunogenicity When HIL-214 is Concomitantly Administered With Routine Pediatric Vaccines in Healthy Infants

NCT05836012 is registered in ClinicalTrials.gov with HilleVax as lead sponsor.

NCT NCT05836012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05836012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-country, Randomized, Double-blind, Placebo-controlled Trial to Evaluate Safety and Immunogenicity When HIL-214 is Concomitantly Administered With Routine Pediatric Vaccines in Healthy Infants
Lead sponsor
HilleVax
Phase
Phase 2/3
Overall status
Completed
Start date
June 10, 2023
Completion date
July 8, 2024
Enrollment
329 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteritis